Table 2 Selection of risk-related pathways

Measles

2.03E-29

DDX58, IL2RB, IFIH1, JAK2, FAS

Antigen processing and presentation

7.42E-19

KLRC4, HLA-DRB5, HLA-E, HLA-DMA, HLA-DQA1, HLA-DRA

Rheumatoid arthritis

1.70E-13

CD86, CD80, HLA-DRB5, ATP6V1H, HLA-DMA, HLA-DQA1, HLA-DRA

Phagosome

5.84E-12

FCGR1A, HLA-DRB5, ITGB5, ATP6V1H, CLEC7A, HLA-E, HLA-DMA, HLA-DQA1, HLA-DRA

Systemic lupus erythematosus

1.31E-11

HIST1H2AC, CD86, CD80, FCGR1A, HLA-DRB5, HLA-DMA, HLA-DQA1, HLA-DRA

Herpes simplex infection

1.18E-06

DDX58, HMGN1, IFIH1, GTF2IRD1, CASP8, HLA-DRB5, JAK2, FAS, HLA-E, HLA-DMA, HLA-DQA1, HLA-DRA

Inflammatory bowel disease (IBD)

1.14E-05

IL18RAP, HLA-DRB5, HLA-DMA, HLA-DQA1, HLA-DRA

Tuberculosis

0.000357276

FCGR1A, CASP8, HLA-DRB5, FCER1G, ATP6V1H, JAK2, CLEC7A, HLA-DMA, HLA-DQA1, HLA-DRA

Type I diabetes mellitus

0.001284502

CD86, CD80, HLA-DRB5, FAS, HLA-E, HLA-DMA, HLA-DQA1, HLA-DRA

Toxoplasmosis

0.001643

CASP8, HLA-DRB5, JAK2, BIRC3, HLA-DMA, HLA-DQA1, HLA-DRA